Strategic partnerships TAmiRNA is actively expanding its network through European RNA alliances, recently partnering with Lexogen and joining the European RNA Alliance (ERA). This indicates openness to collaboration, potential co-development or joint commercial opportunities in RNA biomarker platforms and diagnostics.

Biomarker focus Specialization in circulating microRNA biomarkers for diagnosis and prediction across musculoskeletal, cardiovascular, and metabolic diseases suggests target markets and disease areas where partnerships with diagnostics developers, clinical laboratories, and pharma could be fruitful.

Emerging capabilities Introduction of the miND workflow for miRNA NGS discovery and a lyophilized miND spike-in kit demonstrates ongoing methodological advancements and productization potential that could be licensed, co-developed, or sold to sequencing service providers and research labs.

Engagement & events Active participation in RNA leaders conferences, EV-focused events, and ISEV conferences indicates a proactive sales approach and opportunities to generate leads, pilot collaborations, and speaking engagements to elevate visibility among potential customers.

Financial positioning Current revenue under CHF, USD 1 million range with modest funding signals a need for grant, partner-funded projects, or contract research arrangements. This can guide sales conversations toward sponsored studies, feasibility collaborations, and milestone-based deals with pharma, CROs, or diagnostic companies.